IE911971A1 - Treatment of disease - Google Patents

Treatment of disease

Info

Publication number: IE911971A1
Authority: IE; Ireland
Prior art keywords: use according; compound; substituent; formula; phenyl
Prior art date: 1990-06-11

Application number

IE197191A

Other languages

English (en)

Original Assignee

Fmc Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-06-11

Filing date

1991-06-10

Publication date

1991-12-18

1991-06-10 Application filed by Fmc Corp filed Critical Fmc Corp

1991-12-18 Publication of IE911971A1 publication Critical patent/IE911971A1/en

Links

238000011282 treatment Methods 0.000 title abstract description 14
201000010099 disease Diseases 0.000 title description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 5
150000001875 compounds Chemical class 0.000 claims abstract description 56
238000006243 chemical reaction Methods 0.000 claims abstract description 14
UHSGPDMIQQYNAX-UHFFFAOYSA-N protoporphyrinogen Chemical compound C1C(=C(C=2C=C)C)NC=2CC(=C(C=2CCC(O)=O)C)NC=2CC(N2)=C(CCC(O)=O)C(C)=C2CC2=C(C)C(C=C)=C1N2 UHSGPDMIQQYNAX-UHFFFAOYSA-N 0.000 claims abstract description 10
230000002255 enzymatic effect Effects 0.000 claims abstract description 9
150000003278 haem Chemical class 0.000 claims abstract description 9
208000017733 acquired polycythemia vera Diseases 0.000 claims abstract description 5
239000003112 inhibitor Substances 0.000 claims abstract description 5
208000037244 polycythemia vera Diseases 0.000 claims abstract description 5
208000036796 hyperbilirubinemia Diseases 0.000 claims abstract description 3
210000004962 mammalian cell Anatomy 0.000 claims abstract description 3
239000003795 chemical substances by application Substances 0.000 claims description 29
210000004027 cell Anatomy 0.000 claims description 26
-1 aryl triazolinone Chemical compound 0.000 claims description 24
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 14
239000004009 herbicide Substances 0.000 claims description 13
125000001424 substituent group Chemical group 0.000 claims description 12
230000002363 herbicidal effect Effects 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 6
108020001991 Protoporphyrinogen Oxidase Proteins 0.000 claims description 4
102000005135 Protoporphyrinogen oxidase Human genes 0.000 claims description 4
125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 3
125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 3
229910014033 C-OH Inorganic materials 0.000 claims description 3
229910014570 C—OH Inorganic materials 0.000 claims description 3
125000000623 heterocyclic group Chemical group 0.000 claims description 3
239000001257 hydrogen Substances 0.000 claims description 3
229910052739 hydrogen Inorganic materials 0.000 claims description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
JDTMUJBWSGNMGR-UHFFFAOYSA-N 1-nitro-4-phenoxybenzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC1=CC=CC=C1 JDTMUJBWSGNMGR-UHFFFAOYSA-N 0.000 claims 6
125000004453 alkoxycarbonyl group Chemical group 0.000 claims 4
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 4
125000000217 alkyl group Chemical group 0.000 claims 2
125000003262 carboxylic acid ester group Chemical group [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 claims 2
239000003814 drug Substances 0.000 claims 2
IZBNNCFOBMGTQX-UHFFFAOYSA-N etoperidone Chemical group O=C1N(CC)C(CC)=NN1CCCN1CCN(C=2C=C(Cl)C=CC=2)CC1 IZBNNCFOBMGTQX-UHFFFAOYSA-N 0.000 claims 2
229960005437 etoperidone Drugs 0.000 claims 2
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
125000003545 alkoxy group Chemical group 0.000 claims 1
125000004429 atom Chemical group 0.000 claims 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
229910052757 nitrogen Inorganic materials 0.000 claims 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
238000012360 testing method Methods 0.000 description 25
102000004190 Enzymes Human genes 0.000 description 20
108090000790 Enzymes Proteins 0.000 description 20
239000000463 material Substances 0.000 description 16
230000002401 inhibitory effect Effects 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
210000003763 chloroplast Anatomy 0.000 description 11
239000000243 solution Substances 0.000 description 11
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
235000019804 chlorophyll Nutrition 0.000 description 9
241000196324 Embryophyta Species 0.000 description 8
238000003556 assay Methods 0.000 description 8
229930002875 chlorophyll Natural products 0.000 description 8
ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 8
239000000725 suspension Substances 0.000 description 8
KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 7
125000003118 aryl group Chemical group 0.000 description 7
239000008366 buffered solution Substances 0.000 description 7
229950003776 protoporphyrin Drugs 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000007788 liquid Substances 0.000 description 6
239000002609 medium Substances 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
240000008067 Cucumis sativus Species 0.000 description 5
102000001554 Hemoglobins Human genes 0.000 description 5
108010054147 Hemoglobins Proteins 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 5
VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
239000002904 solvent Substances 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
239000001110 calcium chloride Substances 0.000 description 4
235000011148 calcium chloride Nutrition 0.000 description 4
229910001628 calcium chloride Inorganic materials 0.000 description 4
239000000203 mixture Substances 0.000 description 4
210000002706 plastid Anatomy 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
235000010799 Cucumis sativus var sativus Nutrition 0.000 description 3
MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 3
238000005273 aeration Methods 0.000 description 3
239000012149 elution buffer Substances 0.000 description 3
230000009483 enzymatic pathway Effects 0.000 description 3
210000003743 erythrocyte Anatomy 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
238000005286 illumination Methods 0.000 description 3
238000002955 isolation Methods 0.000 description 3
239000008188 pellet Substances 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
238000000746 purification Methods 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
241000195493 Cryptophyta Species 0.000 description 2
235000009849 Cucumis sativus Nutrition 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
230000005526 G1 to G0 transition Effects 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
240000004713 Pisum sativum Species 0.000 description 2
235000010582 Pisum sativum Nutrition 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
XQNAUQUKWRBODG-UHFFFAOYSA-N chlornitrofen Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC1=C(Cl)C=C(Cl)C=C1Cl XQNAUQUKWRBODG-UHFFFAOYSA-N 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
239000003599 detergent Substances 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000003337 fertilizer Substances 0.000 description 2
238000000227 grinding Methods 0.000 description 2
238000005534 hematocrit Methods 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000011221 initial treatment Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
238000000034 method Methods 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
239000000575 pesticide Substances 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
239000004033 plastic Substances 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
239000010455 vermiculite Substances 0.000 description 2
229910052902 vermiculite Inorganic materials 0.000 description 2
235000019354 vermiculite Nutrition 0.000 description 2
239000003643 water by type Substances 0.000 description 2
IPPAUTOBDWNELX-UHFFFAOYSA-N (2-ethoxy-2-oxoethyl) 5-[2-chloro-4-(trifluoromethyl)phenoxy]-2-nitrobenzoate Chemical compound C1=C([N+]([O-])=O)C(C(=O)OCC(=O)OCC)=CC(OC=2C(=CC(=CC=2)C(F)(F)F)Cl)=C1 IPPAUTOBDWNELX-UHFFFAOYSA-N 0.000 description 1
VGNCBRNRHXEODV-XXVHXNRLSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-6-dodecoxy-4,7-dihydroxy-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@H](O)[C@H](C(O2)(C(O)=O)C(O)(C(O1)C(O)=O)C(O)=O)OCCCCCCCCCCCC)C1=CC=CC=C1 VGNCBRNRHXEODV-XXVHXNRLSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
CXKAPDFYKAWQRM-UHFFFAOYSA-N 3-chloro-2-(4-chloro-2-fluoro-5-propan-2-yloxyphenyl)-4,5,6,7-tetrahydroindazole Chemical compound C1=C(Cl)C(OC(C)C)=CC(N2C(=C3CCCCC3=N2)Cl)=C1F CXKAPDFYKAWQRM-UHFFFAOYSA-N 0.000 description 1
ZAJBYTSUTBCMRM-UHFFFAOYSA-N 5-(2-methylpyrazol-3-yl)-1,4,5,6-tetrahydrocyclopenta[c]pyrazole-3-carboxylic acid Chemical compound CN1N=CC=C1C1CC(C(C(O)=O)=NN2)=C2C1 ZAJBYTSUTBCMRM-UHFFFAOYSA-N 0.000 description 1
229910000497 Amalgam Inorganic materials 0.000 description 1
239000005484 Bifenox Substances 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
241000195585 Chlamydomonas Species 0.000 description 1
DXXVCXKMSWHGTF-UHFFFAOYSA-N Chlomethoxyfen Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(OC=2C(=CC(Cl)=CC=2)Cl)=C1 DXXVCXKMSWHGTF-UHFFFAOYSA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
101000962225 Escherichia coli (strain K12) Dye-decolorizing peroxidase YfeX Proteins 0.000 description 1
HHMCAJWVGYGUEF-UHFFFAOYSA-N Fluorodifen Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC1=CC=C(C(F)(F)F)C=C1[N+]([O-])=O HHMCAJWVGYGUEF-UHFFFAOYSA-N 0.000 description 1
DHAHEVIQIYRFRG-UHFFFAOYSA-N Fluoroglycofen Chemical compound C1=C([N+]([O-])=O)C(C(=O)OCC(=O)O)=CC(OC=2C(=CC(=CC=2)C(F)(F)F)Cl)=C1 DHAHEVIQIYRFRG-UHFFFAOYSA-N 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
102000016761 Haem oxygenases Human genes 0.000 description 1
108050006318 Haem oxygenases Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
206010023126 Jaundice Diseases 0.000 description 1
206010023138 Jaundice neonatal Diseases 0.000 description 1
SUSRORUBZHMPCO-UHFFFAOYSA-N MC-4379 Chemical compound C1=C([N+]([O-])=O)C(C(=O)OC)=CC(OC=2C(=CC(Cl)=CC=2)Cl)=C1 SUSRORUBZHMPCO-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
201000006346 Neonatal Jaundice Diseases 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
OQMBBFQZGJFLBU-UHFFFAOYSA-N Oxyfluorfen Chemical compound C1=C([N+]([O-])=O)C(OCC)=CC(OC=2C(=CC(=CC=2)C(F)(F)F)Cl)=C1 OQMBBFQZGJFLBU-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241000282887 Suidae Species 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000370 acceptor Substances 0.000 description 1
NUFNQYOELLVIPL-UHFFFAOYSA-N acifluorfen Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(OC=2C(=CC(=CC=2)C(F)(F)F)Cl)=C1 NUFNQYOELLVIPL-UHFFFAOYSA-N 0.000 description 1
239000011149 active material Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
239000012472 biological sample Substances 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
238000004820 blood count Methods 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
235000013877 carbamide Nutrition 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
229940125532 enzyme inhibitor Drugs 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000012953 feeding on blood of other organism Effects 0.000 description 1
BGZZWXTVIYUUEY-UHFFFAOYSA-N fomesafen Chemical compound C1=C([N+]([O-])=O)C(C(=O)NS(=O)(=O)C)=CC(OC=2C(=CC(=CC=2)C(F)(F)F)Cl)=C1 BGZZWXTVIYUUEY-UHFFFAOYSA-N 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000009472 formulation Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
125000001475 halogen functional group Chemical group 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
108700043100 hereditary spherocytic hemolytic Anemia Proteins 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
229960001330 hydroxycarbamide Drugs 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
CONWAEURSVPLRM-UHFFFAOYSA-N lactofen Chemical compound C1=C([N+]([O-])=O)C(C(=O)OC(C)C(=O)OCC)=CC(OC=2C(=CC(=CC=2)C(F)(F)F)Cl)=C1 CONWAEURSVPLRM-UHFFFAOYSA-N 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000031700 light absorption Effects 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
231100001252 long-term toxicity Toxicity 0.000 description 1
238000000464 low-speed centrifugation Methods 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
AHGMXAFUHVRQAD-UHFFFAOYSA-N methyl 5-[2-chloro-4-(trifluoromethyl)phenoxy]-2-nitrobenzoate Chemical group C1=C([N+]([O-])=O)C(C(=O)OC)=CC(OC=2C(=CC(=CC=2)C(F)(F)F)Cl)=C1 AHGMXAFUHVRQAD-UHFFFAOYSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
230000004899 motility Effects 0.000 description 1
LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 1
XITQUSLLOSKDTB-UHFFFAOYSA-N nitrofen Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC1=CC=C(Cl)C=C1Cl XITQUSLLOSKDTB-UHFFFAOYSA-N 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
229920002113 octoxynol Polymers 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
230000037039 plant physiology Effects 0.000 description 1
239000002574 poison Substances 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
150000004032 porphyrins Chemical class 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
231100001251 short-term toxicity Toxicity 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000003774 sulfhydryl reagent Substances 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000012085 test solution Substances 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000004832 voltammetry Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
229910000368 zinc sulfate Inorganic materials 0.000 description 1
239000011686 zinc sulphate Substances 0.000 description 1
235000009529 zinc sulphate Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Emergency Medicine (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

IE197191A 1990-06-11 1991-06-10 Treatment of disease IE911971A1 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US53579490A	1990-06-11	1990-06-11

Publications (1)

Publication Number	Publication Date
IE911971A1 true IE911971A1 (en)	1991-12-18

Family

ID=24135791

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IE197191A IE911971A1 (en)	1990-06-11	1991-06-10	Treatment of disease

Country Status (7)

Country	Link
AU (1)	AU8185491A (cs)
CS (1)	CS176291A3 (cs)
IE (1)	IE911971A1 (cs)
IL (1)	IL98405A0 (cs)
PT (1)	PT97937A (cs)
WO (1)	WO1991019418A1 (cs)
ZA (1)	ZA914435B (cs)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW492975B (en) *	1993-07-26	2002-07-01	Novartis Ag	Tryptase inhibitor
US5939602A (en) *	1995-06-06	1999-08-17	Novartis Finance Corporation	DNA molecules encoding plant protoporphyrinogen oxidase and inhibitor-resistant mutants thereof
US6023012A (en) *	1996-02-28	2000-02-08	Novartis Finance Corporation	DNA molecules encoding plant protoporphyrinogen oxidase
US5767373A (en)	1994-06-16	1998-06-16	Novartis Finance Corporation	Manipulation of protoporphyrinogen oxidase enzyme activity in eukaryotic organisms
US6084155A (en) *	1995-06-06	2000-07-04	Novartis Ag	Herbicide-tolerant protoporphyrinogen oxidase ("protox") genes
CA2247797A1 (en) *	1996-02-28	1997-09-04	Novartis Ag	Promoters from plant protoporphyrinogen oxidase genes
CN103694243B (zh) *	2013-12-20	2015-09-09	中国农业大学	2-取代吡啶基-1,2,4-三唑并[1,2-a]哒嗪化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA818741B (en) *	1980-12-18	1983-07-27	Wellcome Found	Pharmaceutical compounds,preparation,use and intermediates therefor and their preparation
CA1192545A (en) *	1982-02-16	1985-08-27	Glaxo Group Limited	Heterocyclic derivatives as histamine h.sub.2- antagonists
US5025029A (en) *	1986-10-10	1991-06-18	Children's Hospital Medical Center Of Northern California	Method for augmenting fetal hemoglobin
US4820722A (en) *	1987-08-14	1989-04-11	Eli Lilly And Company	Disubstituted tetrazoles and their use as leukotriene antagonists
US4847276A (en) *	1988-09-06	1989-07-11	Merrell Dow Pharmaceuticals Inc.	Treatment of thromobocytosis with 5-(4-chlorophenyl)-2,4-diemthyl-3H-1,2,4-triazole-3-thione

1991
- 1991-06-06 IL IL98405A patent/IL98405A0/xx unknown
- 1991-06-10 IE IE197191A patent/IE911971A1/en unknown
- 1991-06-10 WO PCT/US1991/004087 patent/WO1991019418A1/en not_active Ceased
- 1991-06-10 CS CS911762A patent/CS176291A3/cs unknown
- 1991-06-10 ZA ZA914435A patent/ZA914435B/xx unknown
- 1991-06-10 AU AU81854/91A patent/AU8185491A/en not_active Abandoned
- 1991-06-11 PT PT97937A patent/PT97937A/pt not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU8185491A (en)	1992-01-07
PT97937A (pt)	1992-04-30
WO1991019418A1 (en)	1991-12-26
IL98405A0 (en)	1992-07-15
ZA914435B (en)	1992-03-25
CS176291A3 (en)	1992-08-12

Publication	Publication Date	Title
US5407808A (en)	1995-04-18	Method and composition for photodynamic treatment and detection of tumors
US5298502A (en)	1994-03-29	Method and composition for photodynamic treatment and detection of tumors
AU633537B2 (en)	1993-02-04	Use of certain herbicides in cancer treatment and production of protoporphyrin ix
Costantino et al.	2000	Pharmacological approaches to the treatment of diabetic complications
Rodrigues et al.	2002	Thioridazine interacts with the membrane of mitochondria acquiring antioxidant activity toward apoptosis–potentially implicated mechanisms
Shukla et al.	1989	Glutathione peroxidase and catalase in liver, kidney, testis and brain regions of rats following cadmium exposure and subsequent withdrawal
Bevan et al.	1995	In vivo insulin mimetic effects of pV compounds: role for tissue targeting in determining potency
Blomstrand et al.	1980	Biological effects and metabolic interactions after chronic and acute administration of 4-methylpyrazole and ethanol to rats
IE911971A1 (en)	1991-12-18	Treatment of disease
Haspel et al.	1984	Cytocidal effect of gossypol on cultured murine erythroleukemia cells is prevented by serum protein.
Fornstedt et al.	1991	Vitamin C deficiency facilitates 5‐S‐cysteinyldopamine formation in guinea pig striatum
Wagner et al.	2002	Hydrogen peroxide-induced apoptosis of HL-60 human leukemia cells is mediated by the oxidants hypochlorous acid and chloramines
Böni et al.	1993	Tin-mesoporphyrin inhibits heme oxygenase activity and heme-iron absorption in the intestine
Senthil et al.	2004	Lipid peroxidation and antioxidants status in patients with papillary thyroid carcinoma in India.
Thakar et al.	1991	Effect of antitumor diarylsulfonylureas on in vivo and in vitro mitochondrial structure and functions
Manzione et al.	1988	Development of porphyria cutanea tarda after treatment with cyclophosphamide
Pasantes-Morales	1986	Current concepts on the role of taurine in the retina
Sieber et al.	1973	Effects of hycanthone on rapidly proliferating cells
RU2074719C1 (ru)	1997-03-10	Способ разрушения опухолевых клеток млекопитающих и фармацевтическая композиция для разрушения опухолевых клеток млекопитающих
US4771130A (en)	1988-09-13	Target-entrapped drugs
Macdonald et al.	1985	Iron deficiency anemia: mitochondrial α-glycerophosphate dehydrogenase in guinea pig skeletal muscle
Gumieniczek	2005	Oxidative stress in kidney and liver of alloxan-induced diabetic rabbits: effect of repaglinide
Hiroyoshi et al.	1987	Decreased erythrocyte δ-aminolevulinate dehydratase activity after styrene exposure
Alter et al.	1974	Inhibition of hemoglobin synthesis by cyanate in vitro
Crowell et al.	1997	Chronic toxicity studies of 5-(2-pyrazinyl)-4-methyl-1, 2-dithiole-3-thione, a potential chemopreventive agent